



One Luitpold Drive, Shirley, New York 11967
(631) 924-4000 • (800) 645-1706 • Fax (631) 924-1731

May 7, 2001

Subject: Dexamethasone Sodium Phosphate Injection, USP – Shortage

Dear Healthcare Professional:

Recently, we notified you that there was a shortage of Dexamethasone Sodium Phosphate Injection, USP, due to a change in the raw material, which required FDA approval for the finished dosage form.

American Regent Laboratories, Inc., is pleased to announce that the FDA has approved our supplemental new drug application for Dexamethasone Sodium Phosphate Injection, USP.

A supply of Dexamethasone Sodium Phosphate Injection, USP, has been shipped to wholesalers and we will continue to manufacture and distribute limited quantities for the next few months.

We are requesting that you limit the use of this product to patients in critical need where no other alternative is available until this drug shortage is resolved. Please use good clinical judgment in assessing the need for this drug, so it can be made available to those patients who need it most.

For further information, please call our Customer Service Department or Professional Services Department at 800-645-1706.

Thank you.

Sincerely,

A handwritten signature in black ink, appearing to read "Walter Crozzi", is written over a horizontal line.

Walter Crozzi, R.Ph., M.S., M.B.A.
Director of Marketing and Professional Services